This year’s American Society for Hematology (ASH) annual conference had an estimated 31,000 attendees...
A beautiful dawn @loganairports, and so the #ASH18 madness begins. There are more people carrying poster tubes, and more slides being created and revised around me, than I’ve ever seen before! 😁📊📉📈💻 pic.twitter.com/ifLUckcjiX— David Steensma (@DavidSteensma) November 29, 2018
With more than 5,000 abstracts presented during the meeting, everyone had their pick of favorite research.
Ab therapies are cheap to make-I have not seen any with higher activity than CARs. If Ab becomes front line- Economics will make 10% efficacy OK- but we will still need CARs. But-as just seen in the CAR22 session if the Ab decreases later CAR activity their use is worrisome— R Orentas (@OrentasR) December 2, 2018
#ASH18 #LBA Powerful @ASH_hematology moment. Dr Kanti Rai commenting at 🎤, the arc of CLL, from paying homage to chemo era/and now we are in new targeted therapy era-that we must continue to *work together*across institutions &cooperative groups in this new era #leusm— Naveen Pemmaraju, MD (@doctorpemm) December 4, 2018
Ironically most interesting new data for CAR-T/TCR at #ASH18 is for solid tumors— Andy Biotech (@AndyBiotech) December 3, 2018
Very encouraging 50% (6/12) ORR in epithelial cancers for $GILD/Kite/NCI TCR targeting HPV16 E7 pic.twitter.com/lSUFI9Md3P
A number of breakthrough clinical trials and research demonstrated the potential for change in the standard of care across a variety of hematologic settings…
Really important trial that affects practice right away: Dr. Larocca at #ASH18 shows that after first 9 cycles there is no benefit with continuing Dex for treatment of newly diagnosed myeloma in elderly patients. #ASH18VR @MyelomaTeacher @NorthTxMSG @mtmdphd @BldCancerDoc pic.twitter.com/zGg6KPsxPG— Vincent Rajkumar (@VincentRK) December 2, 2018
CAR-T trials continue to be hard to interpret because they do not use the intention to treat denominator of pts who enrolled on trial & were pheresed— Vinay Prasad MD MPH (@VPplenarysesh) December 1, 2018
This is JULIET from @NEJM corrected for that#ASH18 #ASH2018https://t.co/ZPMG0iCT3s pic.twitter.com/P2s70gH6Yo
“Oh MAIA!” Dara-Rd >>Rd in ASCT intelligible NDMM pts. PFS not reached vs 31.9 mo. HR 0.56, deeper responses. Maybe a little more neutropenia in DRd but o/w well tolerated. Important to note: 80% pts age >70 #mmsm #ASH18 @tanyawildes right? pic.twitter.com/eKbSlHZLku— Nina Shah (@ninashah33) December 4, 2018
AVERT trial: apixaban therapy significantly lowered rate of venous thromboembolism versus placebo among intermediate-to-high-risk ambulatory patients with cancer who were starting chemotherapy. The rate of major bleeding episodes was higher with apixaban than with placebo. #ASH18— NEJM (@NEJM) December 4, 2018
Also, attendees tackled global health initiatives, ranging from sickle cell disease...
When a #SickleCell patient hits the ER with pain, they should get pain meds IMMEDIATELY. A hefty first dose of pain meds can result in better outcomes. They do not need your narrative, suspicion or discrimination. They need your help. Be a champion for them. #ASH18— Ahmar U. Zaidi, MD (@ahmaruroojzaidi) December 3, 2018
To improving physician wellness...
Dear colleagues attending #ASH18 , if you come across any presentation claiming "tolerable" or "acceptable" or "manageable" toxicities, please email the speaker a link to this paper. Thank you. https://t.co/qNyUssiAPN pic.twitter.com/kW7Mg9Qm6c— Bishal Gyawali (@oncology_bg) December 1, 2018
...concluding an overall exciting conference!
Illustration by Wendy Gu